Meningococcemia primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Primary Prevention== | ==Primary Prevention== | ||
Current vaccines have polysaccharides of groups A, C, Y, and W-135. No vaccine available presently for group B disease since the polysaccharide is not sufficiently immunogenic to produce a reliable antibody response in humans to be effective. | Current vaccines have polysaccharides of groups A, C, Y, and W-135. No vaccine available presently for group B disease since the polysaccharide is not sufficiently immunogenic to produce a reliable antibody response in humans to be effective. | ||
===Prophylaxis=== | |||
* [[Rifampin]] 600 mg PO q12h x 4 doses total or alternatively [[ciprofloxacin]] 500 mg PO x 1 in patients over 18 who cannot tolerate [[rifampin]] | |||
==References== | ==References== | ||
Revision as of 04:07, 19 February 2013
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia primary prevention On the Web |
|
American Roentgen Ray Society Images of Meningococcemia primary prevention |
|
Risk calculators and risk factors for Meningococcemia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Before antibiotics the case fatality rate was over 50%, particularly dangerous in infants and elderly (84% and 72% respectively). Now it is often as low as 8% in major medical centers.
Primary Prevention
Current vaccines have polysaccharides of groups A, C, Y, and W-135. No vaccine available presently for group B disease since the polysaccharide is not sufficiently immunogenic to produce a reliable antibody response in humans to be effective.
Prophylaxis
- Rifampin 600 mg PO q12h x 4 doses total or alternatively ciprofloxacin 500 mg PO x 1 in patients over 18 who cannot tolerate rifampin